Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...

The FDA approved the first interchangeable biosimilars to aflibercept (Eylea) to treat macular degeneration, according to an announcement from the agency. As interchangeable biosimilars, ...

Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...

Credit: Getty Images. The BLA is supported by data from the pivotal PULSAR and PHOTON trials. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The post hoc analysis used data from the phase 2/3 ...

P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...

Among 41 patients treated with 8-mg aflibercept, five developed mild sterile intraocular inflammation within 1 to 3 days. All cases resolved with treatment and caused no permanent vision loss. Early ...

Please provide your email address to receive an email when new articles are posted on . A non-inferiority comparison between aflibercept and bevacizumab as first-line treatment for macular edema ...

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor first approved for treatment of diabetic macular edema (DME) in July 2014 after several large trials showed it was superior to ...